eMedicine Specialties > Emergency Medicine > Cardiovascular

Patent Ductus Arteriosus

Author: Girish Sethuraman, MD, MPH, Clinical Assistant Instructor, Staff Physician, Department of Emergency Medicine, Kings County Hospital, Downstate Medical Center
Coauthor(s): Christopher I Doty, MD, FAAEM, Assistant Professor of Emergency Medicine, Residency Program Director, Department of Emergency Medicine, Kings County Hospital Center, State University of New York Downstate Medical Center
Contributor Information and Disclosures

Updated: Apr 14, 2008

Introduction

Background

Patent ductus arteriosus (PDA) is the persistence of a normal fetal structure between the left pulmonary artery and the descending aorta. Persistence of this fetal structure beyond 10 days of life is considered abnormal.

For a related CME/CE activity, see CME/CE - A Newborn Presenting in Extremis

Pathophysiology

The ductus is derived from the 6th aortic arch. From the 6th week of fetal life onwards, the ductus is responsible for most of the right ventricular outflow. It contributes to 60% of the total cardiac output throughout the fetal life. Only about 5-10% of its outflow passes through the lungs. The ductus arteriosus is an important structure in fetal development as it contributes to the flow of blood to the rest of the fetal organs and structure. Closure of the ductus before birth may lead to right heart failure. At birth, the ductus normally undergoes closure.

A PDA is variable in its presentation. It may be vary in size from small to large and may not be picked up based on physical exam at birth. The available retrospective data on the natural history of untreated patent ductus arteriosus are poor; however, complications can arise. Spontaneous ductal closure can occur without treatment.

Complications of untreated PDA include bacterial endocarditis, late congestive heart failure (CHF), and the development of pulmonary vascular obstructive disease. PDA can complicate other circulatory or ventilatory abnormalities.

Frequency

United States

PDA is the fifth or sixth most common congenital cardiac defect. It often is associated with other intracardiac structural defects.

PDA represents 5-10% of all congenital heart diseases, excluding those in premature infants. It occurs in approximately 8 of 1000 live premature births. In term infants, the incidence is about 1 in 2000 births. The female-to-male ratio is 2:1.

Mortality/Morbidity

  • Morbidity and mortality rates are directly related to the flow volume through the ductus arteriosus.
  • A large patent ductus arteriosus may cause CHF; if left untreated for a long period, development of pulmonary vascular obstructive disease may occur. Occasionally, the ductus arteriosus patency can be intermittent.
  • It is estimated that left untreated, the mortality rate is 20% by age 20 years, 42% by age 45 years, and 60% mortality rate by age 60 years. An estimated 0.6% per year undergo spontaneous closure.

Race

No data support a race predilection.

Sex

Females are 2-3 times more likely than males to develop PDA.

Age

Patent ductus arteriosus is a common problem in premature infants and is less likely to be noted as gestational age increases to full term. Incidence ranges from 20% in premature infants older than 32 weeks' gestation up to 60% in those younger than 28 weeks' gestation.

Up to 30% of low birth weight infants (<2500 g) develop a patent ductus arteriosus.

Occasionally, an older child is referred with the late discovery of a typical ductus arteriosus murmur (eg, machinery or continuous murmur).

Clinical

History

The history is variable depending on the size of the lesion and the coincident left-to-right shunting of blood through the pulmonary circulation.

  • When the ductus arteriosus is small, no symptoms are present.
  • A ductus arteriosus with a moderate-to-large left-to-right shunt may be associated with a hoarse cry, cough, lower respiratory tract infections, atelectasis, or pneumonia.
  • When the defect is large, CHF with dyspnea and poor weight gain or failure to thrive are the main presentations.

Physical

  • Tachypnea
  • Tachycardia
  • Diaphoresis
  • Cyanosis
  • Bounding peripheral pulses and wide pulse pressure
  • Hyperactive precordium
    • Systolic thrill
    • Occasionally, with increased pulmonary artery pressure, accentuation of the pulmonic component of the second heart sound is heard.
    • A grade 1-4 of 6 continuous or machinery murmur is best heard at the upper left sternal border or left infraclavicular area.
    • An apical diastolic rumble with a large left to right shunt may be present.
    • Occasionally, auscultation of the PDA reveals numerous clicks or noises resembling shaking dice or a bag of rocks.
    • The murmur may be only a systolic ejection murmur, or it may be a crescendo/decrescendo systolic murmur that extends into diastole.
  • Clubbing

Causes

  • Prematurity
  • Low birth weight
  • Prostaglandins
  • Maternal rubella in the first trimester of pregnancy is thought to be a cause of the seasonal incidence of PDA.
  • High altitude and low atmospheric oxygen tension have been associated with persistence of the PDA.
  • Hypoxia

More on Patent Ductus Arteriosus

Overview: Patent Ductus Arteriosus
Differential Diagnoses & Workup: Patent Ductus Arteriosus
Treatment & Medication: Patent Ductus Arteriosus
Follow-up: Patent Ductus Arteriosus
Multimedia: Patent Ductus Arteriosus
References

References

  1. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. Jan 23 2008;CD003481. [Medline].

  2. Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2008;(1):CD003951. [Medline].

  3. Benders MJ, van de Bor M, van Bel F. Doppler sonographic study of the effect of indomethacin on cardiac and pulmonary hemodynamics of the preterm infant. Eur J Ultrasound. May 1999;9(2):107-16. [Medline].

  4. Bensky AS, Raines KH, Hines MH. Late follow-up after thoracoscopic ductal ligation. Am J Cardiol. Aug 1 2000;86(3):360-1. [Medline].

  5. Brook MM, Heymann MA. Patent ductus arteriosus. In: Heart Disease in Infants, Children and Adolescents. Vol I Section III, Part A. 1995:746-64/chap 54.

  6. Burke RP, Jacobs JP, Cheng W, et al. Video-assisted thoracoscopic surgery for patent ductus arteriosus in low birth weight neonates and infants. Pediatrics. Aug 1999;104(2 Pt 1):227-30. [Medline].

  7. Castaneda AR, Jonas RA, Meyer JE. Surgery for infants with congenital heart disease. In: Kirklin JW, Barrett-Boyes BG, eds. Cardiac Surgery. 1993:841-61.

  8. Fyler DC. Patent ductus arteriosus. In: Nadas Pediatric Cardiology. 1992:525-34.

  9. McConnell ME, Adkins SB 3rd, Hannon DW. Heart murmurs in pediatric patients: when do you refer?. Am Fam Physician. Aug 1999;60(2):558-65. [Medline].

  10. Park MK. Specific congenital heart defects: patent ductus arteriosus. In: Pediatric Cardiology for Practitioners. 1988:134-7.

  11. Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation. Oct 24 2006;114(17):1873-82. [Medline].

  12. Silverman NH. Patent ductus arteriosus. In: Pediatric Echocardiography. 1993:167-77.

  13. Snider AR, Serwer GA. Abnormal vascular connections and structures: patent ductus arteriosus. In: Echocardiography in Pediatric Heart Disease. 1990:264-71. [Medline].

  14. Wyllie J. Treatment of patent ductus arteriosus. Semin Neonatol. Dec 2003;8(6):425-32. [Medline].

Further Reading

Keywords

PDA, patent ductus arteriosus, ductal closure, bacterial endocarditis, late congestive heart failure, CHF, development of pulmonary vascular obstructive disease, circulatory abnormalities, ventilatory abnormalities, congenital heart diseases

Contributor Information and Disclosures

Author

Girish Sethuraman, MD, MPH, Clinical Assistant Instructor, Staff Physician, Department of Emergency Medicine, Kings County Hospital, Downstate Medical Center
Girish Sethuraman, MD, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Public Health Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Christopher I Doty, MD, FAAEM, Assistant Professor of Emergency Medicine, Residency Program Director, Department of Emergency Medicine, Kings County Hospital Center, State University of New York Downstate Medical Center
Christopher I Doty, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Mark S Slabinski, MD, FACEP, FAAEM, Vice President, EMP Medical Group
Mark S Slabinski, MD, FACEP, FAAEM is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Ohio State Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Gary Setnik, MD, Chair, Department of Emergency Medicine, Mount Auburn Hospital; Assistant Professor, Division of Emergency Medicine, Harvard Medical School
Gary Setnik, MD is a member of the following medical societies: American College of Emergency Physicians and National Association of EMS Physicians
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Charles V Pollack, Jr, MD, MA, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania College of Medicine; Chairman, Department of Emergency Medicine, Pennsylvania Hospital
Charles V Pollack, Jr, MD, MA, FACEP is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians
Disclosure: sanofi-aventis Honoraria Consulting; sanofi-aventis Honoraria Speaking and teaching; Schering-Polugh Honoraria Consulting; Schering-Plough Honoraria Speaking and teaching; The Medicines Company Honoraria Consulting; GlaxoSmithKline Grant/research funds Other

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.